| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4676 | Seh-in-12 | Novel potent inhibitor of the enzyme soluble epoxide hydrolase (sEH) |
|
| DCC4677 | Sempai | Novel AkaLumine analog, acting asa NIR emission luciferin with the enhanced solubility in water |
|
| DCC4678 | Sen205a | Novel S100B inhibitor |
|
| DCC4679 | Sen461 | Novel Wnt inhibitor/Axin stabilizer |
|
| DCC4680 | Sen-826 | Novel potent antagonist of the Hedgehog pathway |
|
| DCC4681 | Senp1-in-8e | Sentrin-specific protease 1 (SENP1) inhibitor |
|
| DCC4682 | Se-nsaid-8 | Novel selenium-nonsteroidal anti-inflammatory drug (Se-NSAID), inhibiting colorectal cancer (CRC) growth via the inhibition of the cell cycle in G1 and G2/M phases and reduces the cell cycle markers like cyclin E1 and B1 in a dose dependent manner |
|
| DCC4683 | Sephin1 Hydrochloride | Selective inhibitor of the phosphatase regulatory subunit PPP1R15A (R15A) that prolong the benefit of eIF2α phosphorylation, thereby protecting cells from proteostatic defects |
|
| DCC4684 | Ser@tpp@cur | Novel mitochondrial KIM-1 receptor modulator to be specifically internalized by renal tubular epithelial cells via KIM-1 receptor-mediated endocytosis and then actively distributed in mitochondria under the effect of TPP, effectively ameliorating injured |
|
| DCC4685 | Sert Inhibitor 69419 | Novel serotonin reuptake inhibitor |
|
| DCC4686 | Sertaconazole | Cytochrome P450 14α-demethylase inhibitor, also acting as a BuChE-IDO1 inhibitor |
|
| DCC4687 | Setastine | Highly selective H1 receptor antagonist |
|
| DCC4688 | Sethrrs Inhibitor 36j | The first-in-class triple-site aaRS inhibitor, targeting Salmonella enterica threonyl-tRNA synthetase (SeThrRS) with IC 50 = 19 nM and K d = 35.4 nM |
|
| DCC4689 | Setin-1 | The most potent inhibitor of Set7, inhibiting the KMTase G9a |
|
| DCC4690 | Trichomonacid | Novel inhibitor of Mycobacterium marinum MelF (Rv1936), exhibiting bacteriostatic/bactericidal activity against M. marinum and M. tuberculosis in vitro |
|
| DCC4691 | Seviteronel | Novel potent CYP17 lyase inhibitor, inhibiting androgen production without mineralocorticoid excess or cortisol depletion |
|
| DCC4692 | sew05920 | Novel telomerase inhibitor |
|
| DCC4693 | Sew-05929 | The First potent SecA inhibitor |
|
| DCC4694 | Sf-1-087 | Potent and selective STAT5 inhibitor |
|
| DCC4695 | Sf-22 (npy Y2 Antagonist) | Potent, selective, and highly brain-penetrant NPY Y2 receptor antagonist |
|
| DCC4696 | Sf2535 | Novel dual inhibitor of BRD4 and PI3K, inhibiting BRD4, PI3Kα, PI3Kδ, and PI3Kγ with IC 50 values of 277, 714, 27, and 1170 nM, respectively |
|
| DCC4697 | Sfom-0046 | Novel anticancer agent, arresting cell cycle in S-phase and causes DNA replication stress leading to the phosphorylation of H2AX into gamma-H2AX |
|
| DCC4698 | Sfrp-1 Inhibitor-1 | Cell-permeable antagonist of secreted frizzled related protein-1(sFRP-1), inhibiting Wnt-3/frizzled interaction and restoring cellular response to Wnt-3 stimulation |
|
| DCC4699 | Sfti-1 | Highly Potent and Selective Plasmin Inhibitor, Attenuating Fibrinolysis in Plasma |
|
| DCC4700 | Sgc-camkk2-1 | Novel probe for CAMKK2/CAMKK1 |
|
| DCC4701 | Sgc-clk-1 | Novel probe for CLK1, CLK2, and CLK4 |
|
| DCC4702 | Sgc-gak-1n | Negative control for SGC-GAK-1 (GLXC-31266) |
|
| DCC4703 | Sge201 | Novel potent allosteric modulator of N-methyl-D-aspartate receptors (NMDAR) |
|
| DCC4704 | Sgi-10067 | PKM2 activator, potently inhibiting proliferation of cancer cells in media lacking serine |
|
| DCC4705 | Sgi-9380 | PKM2 activator, potently inhibiting proliferation of cancer cells in media lacking serine |
|
